Previous 10 | Next 10 |
Rare disease-focused biotech Sarepta Therapeutics ( NASDAQ: SRPT ) lost ~4% pre-market Friday after announcing a share exchange agreement with some of its convertible debt holders. Per the terms of the agreement signed on Mar. 02, Sarepta’s ( SRPT ) 1.50% convertible se...
Shares of Sarepta Therapeutics (NASDAQ: SRPT) rose 24% this week as of Thursday afternoon, according to data provided by S&P Global Market Intelligence . The biotech company, which focuses on precision gene therapies, closed out at $123.06 a share last week, then rose to a 52-...
Earnings news remained a key mover for individual stocks in Wednesday's midday trading. Tupperware Brands ( NYSE: TUP ) and Abercrombie & Fitch ( ANF ) both lost ground on the release of financial figures. Meanwhile, Duolingo ( DUOL ) headed in the opposite direction on it...
Gainers: Reata Pharmaceuticals ( RETA ) +176% . OncoSec Medical ( ONCS ) +118% . Sarepta Therapeutics ( SRPT ) +24% . PetIQ ( PETQ ) +17% . Amphastar Pharmaceuticals ( AMPH ) +15% . Losers: Novavax ( NVAX ) -24% . ...
The stock market finished the month of February lower, giving back some of its gains from January. However, as investors prepared for the first day of March, the Nasdaq Composite (NASDAQINDEX: ^IXIC) tried to rebound, with gains of about 0.2% in futures trading before the market opened We...
Sarepta Therapeutics ( NASDAQ: SRPT ) added ~18% pre-market Wednesday as Morgan Stanly upgraded it after the company said that the FDA would not hold an advisory committee meeting on its marketing application for gene therapy SRP-9001. Sarepta ( SRPT ) made these remarks with ...
Sarepta Therapeutics, Inc. (SRPT) Q4 2022 Earnings Conference Call February 28, 2023 16:30 ET Company Participants Mary Jenkins - Senior Manager of Investor Relations Doug Ingram - President & Chief Executive Officer Louise Rodino-Klapac - Executive Vice President,...
Image source: The Motley Fool. Sarepta Therapeutics (NASDAQ: SRPT) Q4 2022 Earnings Call Feb 28, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript
Sarepta Therapeutics ( NASDAQ: SRPT ) is up 16% in after-hours trading after it was informed by the US FDA that it would not need to hold an advisory committee for its Biologics License Application for SRP-9001 for Duchenne muscular dystrophy. The candidate, also known as del...
Sarepta Therapeutics press release ( NASDAQ: SRPT ): Q4 GAAP EPS of -$1.24 misses by $0.06 . Revenue of $258.4M (+28.3% Y/Y) beats by $7.89M . Company had approximately $2.0 billion and $2.1 billion in cash, cash equivalents, investments and long-term restricted cash a...
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2024 financial results after the Nasdaq Global Market closes on Wednesday, May 1, 2024. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discu...
2024-04-06 08:45:00 ET The biotech industry can be attractive for several reasons. Many leading biotechs develop innovative, life-saving therapies, a business that will only be phased out once we find an all-purpose cure for all illnesses. Further, biotechs often deliver better-than-average...
2024-03-19 10:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...